|MDACC Study No:||2012-0598 (clinicaltrials.gov NCT No: NCT01904682)|
|Title:||Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 Myelodysplastic Syndrome Patients Based on International Prognostic Scoring System|
|Principal Investigator:||Elias Jabbour|
|Treatment Agent:||RIGOSERTIB SODIUM (ON 01910.Na)|
|Study Description:||The goal of Part 1 of this clinical research study was to find the highest |
tolerable dose of rigosertib that can be given to patients with MDS. Part 1 is
The goal of Part 2 of this study is to learn if rigosertib can help to control
MDS. The safety of this drug will also be studied.